Impact of Dexmedetomidine Infusion on Opioid and Benzodiazepine Doses in Ventilated Pediatric Patients in the Cardiac Intensive Care Unit
CONCLUSION: While in patients ventilated < 5 days opioids initially increased and then quickly decreased in the 72 h following DEX initiation, among patients ventilated ≥ 5 days opioids doubled, then decreased only minimally; benzodiazepines decreased minimally in both groups, although more slowly in the long-ventilation cohort. These findings may inform decision-making on timing of DEX initiation in ventilated patients already being treated with opioid or benzodiazepine infusions.PMID:37550522 | DOI:10.1007/s40272-023-00587-6 (Source: Paediatric Drugs)
Source: Paediatric Drugs - August 7, 2023 Category: Pediatrics Authors: Reuth Nir Francesca Sperotto Manasee Godsay Minmin Lu John N Kheir Source Type: research
Impact of Dexmedetomidine Infusion on Opioid and Benzodiazepine Doses in Ventilated Pediatric Patients in the Cardiac Intensive Care Unit
CONCLUSION: While in patients ventilated < 5 days opioids initially increased and then quickly decreased in the 72 h following DEX initiation, among patients ventilated ≥ 5 days opioids doubled, then decreased only minimally; benzodiazepines decreased minimally in both groups, although more slowly in the long-ventilation cohort. These findings may inform decision-making on timing of DEX initiation in ventilated patients already being treated with opioid or benzodiazepine infusions.PMID:37550522 | DOI:10.1007/s40272-023-00587-6 (Source: Paediatric Drugs)
Source: Paediatric Drugs - August 7, 2023 Category: Pediatrics Authors: Reuth Nir Francesca Sperotto Manasee Godsay Minmin Lu John N Kheir Source Type: research
Impact of Dexmedetomidine Infusion on Opioid and Benzodiazepine Doses in Ventilated Pediatric Patients in the Cardiac Intensive Care Unit
CONCLUSION: While in patients ventilated < 5 days opioids initially increased and then quickly decreased in the 72 h following DEX initiation, among patients ventilated ≥ 5 days opioids doubled, then decreased only minimally; benzodiazepines decreased minimally in both groups, although more slowly in the long-ventilation cohort. These findings may inform decision-making on timing of DEX initiation in ventilated patients already being treated with opioid or benzodiazepine infusions.PMID:37550522 | DOI:10.1007/s40272-023-00587-6 (Source: Paediatric Drugs)
Source: Paediatric Drugs - August 7, 2023 Category: Pediatrics Authors: Reuth Nir Francesca Sperotto Manasee Godsay Minmin Lu John N Kheir Source Type: research
Impact of Dexmedetomidine Infusion on Opioid and Benzodiazepine Doses in Ventilated Pediatric Patients in the Cardiac Intensive Care Unit
CONCLUSION: While in patients ventilated < 5 days opioids initially increased and then quickly decreased in the 72 h following DEX initiation, among patients ventilated ≥ 5 days opioids doubled, then decreased only minimally; benzodiazepines decreased minimally in both groups, although more slowly in the long-ventilation cohort. These findings may inform decision-making on timing of DEX initiation in ventilated patients already being treated with opioid or benzodiazepine infusions.PMID:37550522 | DOI:10.1007/s40272-023-00587-6 (Source: Paediatric Drugs)
Source: Paediatric Drugs - August 7, 2023 Category: Pediatrics Authors: Reuth Nir Francesca Sperotto Manasee Godsay Minmin Lu John N Kheir Source Type: research
Impact of Dexmedetomidine Infusion on Opioid and Benzodiazepine Doses in Ventilated Pediatric Patients in the Cardiac Intensive Care Unit
CONCLUSION: While in patients ventilated < 5 days opioids initially increased and then quickly decreased in the 72 h following DEX initiation, among patients ventilated ≥ 5 days opioids doubled, then decreased only minimally; benzodiazepines decreased minimally in both groups, although more slowly in the long-ventilation cohort. These findings may inform decision-making on timing of DEX initiation in ventilated patients already being treated with opioid or benzodiazepine infusions.PMID:37550522 | DOI:10.1007/s40272-023-00587-6 (Source: Paediatric Drugs)
Source: Paediatric Drugs - August 7, 2023 Category: Pediatrics Authors: Reuth Nir Francesca Sperotto Manasee Godsay Minmin Lu John N Kheir Source Type: research
Impact of Dexmedetomidine Infusion on Opioid and Benzodiazepine Doses in Ventilated Pediatric Patients in the Cardiac Intensive Care Unit
CONCLUSION: While in patients ventilated < 5 days opioids initially increased and then quickly decreased in the 72 h following DEX initiation, among patients ventilated ≥ 5 days opioids doubled, then decreased only minimally; benzodiazepines decreased minimally in both groups, although more slowly in the long-ventilation cohort. These findings may inform decision-making on timing of DEX initiation in ventilated patients already being treated with opioid or benzodiazepine infusions.PMID:37550522 | DOI:10.1007/s40272-023-00587-6 (Source: Paediatric Drugs)
Source: Paediatric Drugs - August 7, 2023 Category: Pediatrics Authors: Reuth Nir Francesca Sperotto Manasee Godsay Minmin Lu John N Kheir Source Type: research
Impact of Dexmedetomidine Infusion on Opioid and Benzodiazepine Doses in Ventilated Pediatric Patients in the Cardiac Intensive Care Unit
CONCLUSION: While in patients ventilated < 5 days opioids initially increased and then quickly decreased in the 72 h following DEX initiation, among patients ventilated ≥ 5 days opioids doubled, then decreased only minimally; benzodiazepines decreased minimally in both groups, although more slowly in the long-ventilation cohort. These findings may inform decision-making on timing of DEX initiation in ventilated patients already being treated with opioid or benzodiazepine infusions.PMID:37550522 | DOI:10.1007/s40272-023-00587-6 (Source: Paediatric Drugs)
Source: Paediatric Drugs - August 7, 2023 Category: Pediatrics Authors: Reuth Nir Francesca Sperotto Manasee Godsay Minmin Lu John N Kheir Source Type: research
Fetal, Preterm, and Term Neonate Exposure to Remifentanil: A Systematic Review of Efficacy and Safety
CONCLUSIONS: Remifentanil appears to be effective and safe in the short term in preterm and full-term neonates. However, its safety is compromised by the risk of chest wall rigidity. It should be used in appropriate neonatal units and in the presence of physicians able to monitor its side effects. Long-term outcomes have not been evaluated, to our knowledge.PMID:37541994 | DOI:10.1007/s40272-023-00583-w (Source: Paediatric Drugs)
Source: Paediatric Drugs - August 4, 2023 Category: Pediatrics Authors: Arielle Maroni Marie-St éphanie Aubelle Cl ément Chollat Source Type: research
Fetal, Preterm, and Term Neonate Exposure to Remifentanil: A Systematic Review of Efficacy and Safety
CONCLUSIONS: Remifentanil appears to be effective and safe in the short term in preterm and full-term neonates. However, its safety is compromised by the risk of chest wall rigidity. It should be used in appropriate neonatal units and in the presence of physicians able to monitor its side effects. Long-term outcomes have not been evaluated, to our knowledge.PMID:37541994 | DOI:10.1007/s40272-023-00583-w (Source: Paediatric Drugs)
Source: Paediatric Drugs - August 4, 2023 Category: Pediatrics Authors: Arielle Maroni Marie-St éphanie Aubelle Cl ément Chollat Source Type: research
Fetal, Preterm, and Term Neonate Exposure to Remifentanil: A Systematic Review of Efficacy and Safety
CONCLUSIONS: Remifentanil appears to be effective and safe in the short term in preterm and full-term neonates. However, its safety is compromised by the risk of chest wall rigidity. It should be used in appropriate neonatal units and in the presence of physicians able to monitor its side effects. Long-term outcomes have not been evaluated, to our knowledge.PMID:37541994 | DOI:10.1007/s40272-023-00583-w (Source: Paediatric Drugs)
Source: Paediatric Drugs - August 4, 2023 Category: Pediatrics Authors: Arielle Maroni Marie-St éphanie Aubelle Cl ément Chollat Source Type: research
Effectiveness and Safety of Ustekinumab for Pediatric Inflammatory Bowel Disease: A Systematic Review
CONCLUSIONS: According to low-quality evidence mainly from cohort studies and case series, approximately one half of patients with CD and UC/IBD-U achieved remission at 1 year. Ustekinumab has a reasonable safety profile and dose optimization is frequently required. Data on the long-term benefit and high-quality evidence are still needed.PMID:37528211 | DOI:10.1007/s40272-023-00586-7 (Source: Paediatric Drugs)
Source: Paediatric Drugs - August 1, 2023 Category: Pediatrics Authors: Shengbo Fang Sixi Zhang Chunyan Zhang Libo Wang Source Type: research
Effectiveness and Safety of Ustekinumab for Pediatric Inflammatory Bowel Disease: A Systematic Review
CONCLUSIONS: According to low-quality evidence mainly from cohort studies and case series, approximately one half of patients with CD and UC/IBD-U achieved remission at 1 year. Ustekinumab has a reasonable safety profile and dose optimization is frequently required. Data on the long-term benefit and high-quality evidence are still needed.PMID:37528211 | DOI:10.1007/s40272-023-00586-7 (Source: Paediatric Drugs)
Source: Paediatric Drugs - August 1, 2023 Category: Pediatrics Authors: Shengbo Fang Sixi Zhang Chunyan Zhang Libo Wang Source Type: research
Effectiveness and Safety of Ustekinumab for Pediatric Inflammatory Bowel Disease: A Systematic Review
CONCLUSIONS: According to low-quality evidence mainly from cohort studies and case series, approximately one half of patients with CD and UC/IBD-U achieved remission at 1 year. Ustekinumab has a reasonable safety profile and dose optimization is frequently required. Data on the long-term benefit and high-quality evidence are still needed.PMID:37528211 | DOI:10.1007/s40272-023-00586-7 (Source: Paediatric Drugs)
Source: Paediatric Drugs - August 1, 2023 Category: Pediatrics Authors: Shengbo Fang Sixi Zhang Chunyan Zhang Libo Wang Source Type: research
Golimumab in Children with Chronic Recurrent Multifocal Osteomyelitis: A Case Series and Review of the Literature
CONCLUSION: In our experience, golimumab has been shown to be a safe and effective therapy for CRMO and demonstrated improvement in paradoxical psoriasis in many patients. Longer follow-up periods would be helpful to develop longer term outcomes data for patients with CRMO and overall paradoxical psoriasis risk.PMID:37479948 | DOI:10.1007/s40272-023-00581-y (Source: Paediatric Drugs)
Source: Paediatric Drugs - July 21, 2023 Category: Pediatrics Authors: Claire Yang Natalie Rosenwasser Xing Wang Zheng Xu Joshua Scheck Markus D Boos Deepti Gupta Heather A Brandling-Bennet Robert Sidbury Ramesh S Iyer Yongdong Zhao Source Type: research
Golimumab in Children with Chronic Recurrent Multifocal Osteomyelitis: A Case Series and Review of the Literature
CONCLUSION: In our experience, golimumab has been shown to be a safe and effective therapy for CRMO and demonstrated improvement in paradoxical psoriasis in many patients. Longer follow-up periods would be helpful to develop longer term outcomes data for patients with CRMO and overall paradoxical psoriasis risk.PMID:37479948 | DOI:10.1007/s40272-023-00581-y (Source: Paediatric Drugs)
Source: Paediatric Drugs - July 21, 2023 Category: Pediatrics Authors: Claire Yang Natalie Rosenwasser Xing Wang Zheng Xu Joshua Scheck Markus D Boos Deepti Gupta Heather A Brandling-Bennet Robert Sidbury Ramesh S Iyer Yongdong Zhao Source Type: research
